ArticlePancreas2017
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Article in Pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2021Pooled it
- Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.The journal of pathology. Clinical research · 2021Pooled it
- Immature stroma and high infiltration of CD15Cancer science · 2024Article
- Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA.Molecular biology reports · 2023Article
- Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.NPJ precision oncology · 2023Article
- Distribution characteristics and clinical significance of infiltrating T cells in the tumor microenvironment of pancreatic cancer.Oncology letters · 2023Article
- Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.JCI insight · 2022Article
- Review
- Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.Journal of advanced research · 2022Article
- The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.Pharmacology & therapeutics · 2022Review
- Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.International immunopharmacology · 2022Article
- Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.British journal of cancer · 2022Article
- Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer.Frontiers in immunology · 2022Review
- The effect of neoadjuvant chemotherapy on the tumor immune microenvironment in gastrointestinal tumors.Frontiers in oncology · 2022Review
- Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma.Clinical & translational immunology · 2022Article
- Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021Article
- Review
- An Efficient Prognostic Immune Scoring System For Colorectal Cancer Patients With Peritoneal Metastasis.Oncoimmunology · 2021Article
- Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2021Article
- NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype.Oncoimmunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesThe aim of this study was to examine tumor-infiltrating lymphocytes (TILs) and their prognostic value in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy.
methodsIntratumoral CD4, CD8, and FOXP3 lymphocytes were examined by immunohistochemistry using a computer-assisted quantitative analysis in 136 PDAC patients who received neoadjuvant therapy and pancreaticoduodenectomy. The results were correlated with clinicopathological parameters and survival.
resultsHigh CD4 TILs in treated PDAC were associated with high CD8 TILs (P = 0.003), differentiation (P = 0.04), and a lower frequency of recurrence (P = 0.02). Patients with high CD4 TILs had longer disease-free survival and overall survival (OS) than did patients with low CD4 TILs (P < 0.01). The median OS of patients with a high CD8/FOXP3 lymphocyte ratio (39.5 [standard deviation, 6.1] months) was longer than that of patients with a low CD8/FOXP3 lymphocyte ratio (28.3 [standard deviation, 2.3] months; P = 0.01). In multivariate analysis, high CD4 TILs were an independent prognostic factor for disease-free survival (hazard ratio, 0.49; 95% confidence interval, 0.30-0.81; P = 0.005) and OS (hazard ratio, 0.54; 95% confidence interval, 0.33-0.89; P = 0.02).
conclusionsHigh level of CD4 lymphocytes is associated with tumor differentiation and lower recurrence and is an independent prognostic factor for survival in PDAC patients treated with neoadjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.